The ameliorative effect of SeNPs in prostate cancer was indicated by overexpression of necroptosis related to IRF1 and TNF, a decrease in expression of PSA and AR, and an increase in ROS-mediated necroptosis in PC-3 cells. Here, KLK3 is linked to prostate carcinoma.